| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.51223017 |
| The mechanism of interaction between the VWF A 1 domain and glycoprotein Ibalpha has been elucidated in detail , bringing us closer to understanding how this adhesive bond can oppose the fluid dynamic effects of rapidly flowing blood contributing to platelet adhesion and activation . 0.51223017^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Conformational changes in the A 1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Ibalpha . ^^^ Interaction with glycoprotein Ibalpha was assessed by testing inhibition of monoclonal antibody LJ Ib 1 binding to platelets and inhibition of shear induced platelet aggregation mediated by native vWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein Ibalpha ( GP Ibalpha ; CD 42b ; hereafter GPIBA ) is a component of the cell surface receptor for the von Willebrand factor ( vWf ) on platelets . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Mocarhagin , a novel cobra venom metalloproteinase , cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha . ^^^ Identification of the sulfated tyrosine / anionic sequence Tyr 276 Glu 282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha thrombin . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We demonstrate here that , depending on shearing flow conditions , this process may require vWf binding to glycoprotein Ibalpha , even when alphaIIbbeta 3 is competent to bind adhesive ligands . ^^^ Platelet activation induced solely by high shear stress is initiated by glycoprotein Ibalpha interaction with vWf , but results in aggregation only if the latter can bind concurrently to alphaIIbbeta 3 . ^^^ In contrast , platelets exposed to high shear rate after activation by exogenous agonists such as ADP and epinephrine can aggregate when fibrinogen is the alphaIIbbeta 3 adhesive ligand , yet only if vWf binding to glycoprotein Ibalpha can also occur . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelet membrane glycoprotein Ibalpha ( GPIbalpha ) is a major receptor for von Willebrand factor and thrombin , which plays a key role in the initial development of thrombi . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein Ibalpha contains a binding site for von Willebrand factor through which it mediates platelet adhesion ; GP 5 is required for the complex to bind thrombin with high affinity ; and both GP Ibbeta and GP 9 are necessary for efficient plasma membrane expression of the complex . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Soluble recombinant A 7 ( 6 ) polypeptide strongly perturbed the vWF mediated platelet adhesion to Col 6 under high shear rates , without affecting the binding of the vWF platelet receptor glycoprotein Ibalpha to its cognate ligand A 1 ( vWF ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Distinct structural attributes regulating von Willebrand factor A 1 domain interaction with platelet glycoprotein Ibalpha under flow . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Characterization of liposomes carrying von Willebrand factor binding domain of platelet glycoprotein Ibalpha : a potential substitute for platelet transfusion . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein Ibalpha can mediate endothelial cell migration on von Willebrand factor containing substrata . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Interaction of von Willebrand factor domain A 1 with platelet glycoprotein Ibalpha ( 1 289 ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Targeting of liposomes carrying recombinant fragments of platelet membrane glycoprotein Ibalpha to immobilized von Willebrand factor under flow conditions . ^^^ Liposomes with covalently bound recombinant fragments of platelet membrane glycoprotein Ibalpha that retain the von Willebrand factor ( vWf ) binding function ( rGPIbalpha liposomes ) were prepared . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Modeling and functional analysis of the interaction between von Willebrand factor A 1 domain and glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We have also demonstrated that shear induced surface expression of P selectin as well as microparticle release from platelets depended at least on the interaction between von Willebrand factor and glycoprotein Ibalpha , a platelet surface receptor for the former . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The interaction of von Willebrand factor ( vWF ) with the platelet receptor glycoprotein Ibalpha ( GPIbalpha ) is important for platelet adhesion at high shear stress . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The latter finding demonstrates that direct immobilization on a substrate is not a strict requirement for VWF binding to platelet glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Indeed , at in vivo rheological situations where platelets are flowing with high speed in the bloodstream , the only reaction that can initiate mural thrombogenesis is the interaction of vWF with platelet glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Measurement of the binding forces between von Willebrand factor and variants of platelet glycoprotein Ibalpha using optical tweezers . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A 1 domain . ^^^ Transient interactions of platelet receptor glycoprotein Ibalpha ( GpIbalpha ) and the plasma protein von Willebrand factor ( VWF ) reduce platelet velocity at sites of vascular damage and play a role in haemostasis and thrombosis . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Fluid dynamic conditions that are compatible with the existence of tensile stress on the bonds between glycoprotein Ibalpha ( GPIbalpha ) and the VWF A 1 domain led to Ca ( ++ ) release from intracellular stores ( type alpha / beta peaks ) , which preceded stationary platelet adhesion . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The mucin like macroglycopeptide region of glycoprotein Ibalpha is required for cell adhesion to immobilized von Willebrand factor ( VWF ) under flow but not for static VWF binding . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shielding the front strand beta 3 of the von Willebrand factor A 1 domain inhibits its binding to platelet glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The structural and functional properties of the interaction between the von Willebrand factor A 1 domain and glycoprotein Ibalpha have also been elucidated in greater detail , bringing researchers closer to understanding how this adhesive bond can oppose the fluid dynamic effects of rapidly flowing blood to initiate thrombus formation and , concurrently , contribute to platelet activation . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelet type von Willebrand disease ( PTVWD ) is a bleeding disorder in which an increase of function mutation in glycoprotein Ibalpha ( GPIbalpha ) , with respect to binding of von Willebrand factor ( VWF ) , results in a loss of circulating high molecular weight VWF multimers together with a mild moderate thrombocytopenia . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Filamin A binding to the cytoplasmic tail of glycoprotein Ibalpha regulates von Willebrand factor induced platelet activation . ^^^ We examined the hypothesis that filamin A binding to the cytoplasmic tail of platelet glycoprotein Ibalpha ( GpIbalpha ) is regulated by pathologic shear stress and modulates von Willebrand factor ( VWF ) induced platelet activation . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Crystal structure of von Willebrand factor A 1 domain complexed with snake venom , bitiscetin : insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| A sensitive ristocetin co factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Crystal structure of the wild type von Willebrand factor A 1 glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations . ^^^ The adhesion of platelets to the subendothelium of blood vessels at sites of vascular injury under high shear conditions is mediated by a direct interaction between the platelet receptor glycoprotein Ibalpha ( GpIbalpha ) and the A 1 domain of the von Willebrand factor ( VWF ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shear stress triggers von Willebrand factor ( VWF ) binding to platelet glycoprotein Ibalpha and subsequent integrin alpha ( IIb ) beta ( 3 ) dependent platelet aggregation . ^^^ In addition , during SIPA , platelet degranulation required both extracellular Ca ( 2+ ) and VWF glycoprotein Ibalpha interactions without involving alpha ( IIb ) beta ( 3 ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shear stress induced binding of large and unusually large von Willebrand factor to human platelet glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The alpha 1 helix beta 13 strand spanning Leu 214 to Val 229 of platelet glycoprotein Ibalpha facilitates the interaction with von Willebrand factor : evidence from characterization of the epitope of monoclonal antibody AP 1 . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Botrocetin is a snake venom protein that enhances the affinity of the A 1 domain of plasma von Willebrand factor ( vWF ) for the platelet receptor glycoprotein Ibalpha ( GPIbalpha ) , an event that contributes to bleeding and host death . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Interaction between the platelet glycoprotein Ibalpha ( GPIbalpha ) receptor and its adhesive ligand von Willebrand factor ( VWF ) has a critical role in the process of hemostasis . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Gain of von Willebrand factor binding function by mutagenesis of a species conserved residue within the leucine rich repeat region of platelet glycoprotein Ibalpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Von Willebrand factor ( VWF ) is unable to interact spontaneously with platelets because this interaction requires a conversion of the VWF A 1 domain into a glycoprotein Ibalpha ( GpIbalpha ) binding conformation . ^^^ Von Willebrand factor ( VWF ) is unable to interact spontaneously with platelets because this interaction requires a conversion of the VWF A 1 domain into a glycoprotein Ibalpha ( GpIbalpha ) binding conformation . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We describe here the mechanism of platelet adhesion to immobilized von Willebrand factor ( VWF ) and subsequent formation of platelet derived microparticles mediated by glycoprotein Ibalpha ( GPIbalpha ) under high shear stress . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme linked immunosorbent assay based method : performances in patients with type 2B von Willebrand disease . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| A heterozygous mutation in the VWF A 1 domain gave a R1308P substitution in an interactive site for glycoprotein Ibalpha ( GPIbalpha ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Above this threshold , active A 1 domains become exposed in soluble VWF multimers and can bind to glycoprotein Ibalpha , promoting additional platelet recruitment . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Fourteen individuals from five families with a historical diagnosis of type 2B VWD but with no mutation in the von Willebrand factor gene were re investigated for the possibility of p VWD , using platelet aggregation in the presence of cryoprecipitate . p VWD was confirmed by targeted DNA sequencing of the glycoprotein Ibalpha gene , identifying a heterozygous Glycine 233 Valine substitution . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| R1308L recombinant VWF ( rVWF ) had a higher affinity for the platelet glycoprotein Ibalpha ( GPIbalpha ) receptor than wild type rVWF , R1308C rVWF showing an even higher affinity . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We conclude that the recombinant polypeptides produced by transfection of GpIb alpha cDNA into heterologous cells are secreted , soluble , and can inhibit vWF binding to platelet GpIb / IX . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycocalicin is the external part of platelet glycoprotein Ib alpha ( GPIb alpha ) and contains binding sites for von Willebrand factor and thrombin . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| A monomeric von Willebrand factor fragment , Leu 504 Lys 728 , inhibits von Willebrand factor interaction with glycoprotein Ib 9 [ corrected ] . von Willebrand factor interaction with glycoprotein Ib alpha ( GPIb alpha ) plays a critical role in the initial phase of platelet adhesion at high shear rates , and it may also play a role in platelet thrombus formation in partially occluded arteries . ^^^ Previous studies have indicated that two peptides , Cys 474 Pro 488 ( peptide 153 ) and Ser 692 Pro 708 ( peptide 154 ) , inhibit von Willebrand factor GPIb alpha interaction . ^^^ We have expressed a recombinant fragment of von Willebrand factor , Leu 504 Lys 728 [ corrected ] , with a single intrachain disulfide bond linking residues Cys 509 Cys 695 and examined its ability to inhibit von Willebrand factor GPIb alpha interactions and platelet adhesion at high shear forces . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein Ib alpha ( GpIb alpha ) is a platelet membrane Gp that binds von Willebrand factor and mediates platelet adhesion to subendothelium . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The primary sequences of the three individual glycoprotein ( GP ) chains , GPIb alpha , GPIb beta , and GPIX , comprising the normal platelet GPIb / IX receptor for von Willebrand factor ( vWF ) have recently been determined , opening the possibility for characterization of disorders of this receptor at the molecular level . ^^^ While the roles that leucine tandem repeats may normally play within the GPIb / IX complex are not yet known , the perturbation of such a repeat in GPIb alpha may impair interaction with other components of the complex and / or with the binding of vWF . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We have recently shown that this abnormality is associated with a point mutation resulting in substitution of Val for Gly 233 in platelet membrane glycoprotein Ib alpha ( GPIb alpha ) , a major component of the platelet GPIb / IX receptor for vWF . ^^^ The amphipathic surfaces in the 228 238 region of the Val 233 containing GPIb alpha protein may associate strongly with complementary surfaces during vWF binding to the GPIb / IX receptor complex and may help explain heightened association of vWF with this receptor in PT vWD . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The larger alpha chain ( GpIb alpha ) , a platelet receptor for von Willebrand factor , plays a major role in mediating platelet adhesion to the subendothelium . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Thus , the binding domain for von Willebrand factor resides near the NH 2 terminus of the GPIb alpha chain , whereas the carbohydrate rich region is part of the innermost portion of GPIb and does not appear to be involved in the von Willebrand factor binding function . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein ( GP ) Ib 9 complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal mediated redistribution of the remainder of the complex . ^^^ Cathepsin G resulted in proteolysis of the vWF binding site on GPIb alpha ( defined by monoclonal antibody [ MoAb ] 6D1 ) , as determined by increased supernatant glycocalicin fragment ( a proteolytic product of GPIb alpha ) ; decreased total platelet content of GPIb ; and lack of effect of either cytochalasin B ( an inhibitor of actin polymerization ) , prostaglandin I 2 ( an inhibitor of platelet activation ) , or prior fixation of the platelets . ^^^ In summary , neutrophil cathepsin G modulates the platelet surface expression of the GPIb 9 complex both by proteolysis of the vWF binding site on GPIb alpha and by a cytoskeletal mediated redistribution of the remainder of the complex . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet membrane glycoprotein ( GP ) Ib / IX complex is composed of three polypeptides , GPIb alpha , GPIb beta , and GPIX , and functions as a platelet receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The study of defects in the expression of the GPIb 5 9 complex at the platelet surface leading to pathological disorders , like Bernard Soulier syndrome ( BSS ) , or in the affinity of platelets for vWf , like pseudo von Willebrand disease , has helped to delineate the binding site for vWf on GPIb alpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Guinea pig specific probes for P selectin , von Willebrand factor ( vWF ) , glycoprotein Ib alpha ( GpIb alpha ) , and phosphoglycerate kinase were prepared by using the polymerase chain reaction . ^^^ By Northern blot analysis , P selectin messenger ribonucleic acid ( mRNA ) was primarily expressed in the mature megakaryocyte Celsep subgroup , whereas vWF and GpIb alpha mRNA were expressed at all phases of megakaryocyte maturation . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The addition of cytochalasin B or DNase 1 to disrupt potential GPIb alpha cytoskeletal interactions enhanced the immunoprecipitation of endothelial GPIB alpha , caused HUVEC to round up , and increased HUVEC adhesion to RGD mutant vWF . ^^^ These results indicate that while the VNR is the primary adhesion receptor for vWF , endothelial GPIb alpha can mediate HUVEC attachment to vWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The absence of the amino acid substitution at residue 239 of GPIb alpha in the normal individuals tested , together with the linkage of this substitution to the phenotypic expression of disease in these two families and in a family recently described suggest that this amino acid change is a molecular basis for platelet type vWD , and the substitution may produce a quite similar phenotype to the one reported previously ( Gly to Val at residue 233 of GPIb alpha ) . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The absence of the leucine 179 in a patient ' s GPIb alpha is believed to cause a conformational change in the protein which would account for the lack of binding of most of the MoAbs tested and would be responsible for the absence of von Willebrand factor binding . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Among 6 asymptomatic family members , the patient ' s mother and 2 of his 4 children exhibited approximately 50 % binding of anti GPIb alpha mAb to their platelets by both flow cytometry and direct binding studies using 125I vWF , 125I LJ Ib 1 and 125I LJ Ib 10 mAb . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| On another hand , both EL and CG cleave the amino terminal portion of the GPIb alpha subunit of the GPIb 9 receptor , eliminating the binding site for von Willebrand factor and diminishing the capacity of platelets to interact with this adhesion protein . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein Ib beta ( GPIb beta ) exists in platelets disulfide linked to glycoprotein Ib alpha ( GPIb alpha ) , a major receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Fresh bone marrow cells or plasma cells enriched bone marrow cells after a 48 h in vitro culture in the presence of interleukin 6 were stained by an immuno alkaline phosphatase technique using monoclonal antibodies ( mAb ) to von Willebrand factor , GpIb alpha and beta chain , GpIIb / IIIa and Gp 9 . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Previous studies have localized the GpIb alpha binding domain of vWF to amino acid residues 449 728 , a region containing the vWF A 1 domain . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The vWF binding site has been mapped to one of the three constituent chains , GpIb alpha . ^^^ We have now grafted a portion of the extracellular domain of GpIb alpha containing the vWF binding site onto the transmembrane / intracellular domain of the single chain surface molecule ICAM 1 . ^^^ This study indicates that functional expression of the vWF binding domain of GpIb alpha on the surface of mammalian cells can be obtained in the absence of GpIb beta and GpIX . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| These findings ( 1 ) confirm the synthesis and expression of an MCF 7 protein with homology to platelet GPIb alpha , ( 2 ) confirm that the functional activity of this MCF 7 immunorelated GPIb alpha differs from that of platelet GPIb alpha , and ( 3 ) suggest that MCF 7 immunorelated GPIb alpha in its adhesive interactions with plasma vWf may constitute an initial event in MCF 7 induced platelet aggregation . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| When glycocalicin , the N terminal carbohydrate rich extracellular domain of GPIb alpha exhibiting the vWF binding activity , was added to vWF bound to collagen type 3 , no significant binding of glycocalicin was observed , but it bound to vWF in the presence of botrocetin , a vWF modulator protein isolated from Bothrops jararaca snake venom . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| An affinity matrix made of the caseinoglycopeptide selectively bound the platelet membrane glycoprotein GPIb alpha which contains the von Willebrand factor binding site . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We have constructed a recombinant GPIb alpha fragment containing the latter mutation , Met 239 to Val ( M239V ) and characterized the mutant molecule using two methods , ie , interaction between soluble vWF and immobilized M239V and inhibition of platelet aggregation by purified soluble M239V . ^^^ Spontaneous binding ( ie , binding without any inducers ) was observed between 125I vWF and immobilized M239V but not between 125I vWF and immobilized wild type ( WT ) GPIb alpha . ^^^ The addition of low concentrations of ristocetin ( 0 . 2 mg / mL ) induced specific 125I vWF binding to immobilized M239V , but not to WT GPIb alpha . ^^^ At high concentrations of ristocetin ( 1 . 2 mg / mL ) , both WT GPIb alpha and M239V specifically bound to 125I vWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We found a heterozygous missense mutation in the GPIb alpha gene in a sporadic case with pseudo vWD : Met ( ATG ) to Val ( GTG ) at residue 239 . ^^^ This is the first description of de novo mutation occurred in pseudo vWD and / or platelet GPIb alpha gene . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| To define the potential involvement of glycoprotein Ib alpha ( GPIb alpha ) as an endothelial vWF receptor , we compared cell adhesion to three recombinant vWF , the wild type ( WT rvWF ) and two mutants , RGGS rvWF ( D1746G ) , defective for binding to platelet alphaIIb beta 3 , and deltaA 1 rvWF with a deletion between amino acids 478 and 716 , which does not bind to platelet GPIb alpha . ^^^ Monoclonal antibodies to vWF or GPIb alpha , blocking vWF interaction with platelet GPIb alpha , were unable to inhibit endothelial cell adhesion to rvWF . ^^^ In agreement with the fact that endothelial cell adhesion to vWF appeared independent of the GPIb alpha binding domain , we were unable to detect endothelial surface expression of GPIb alpha by flow cytometry or in cell lysates by immunoprecipitation followed by immunoblotting . ^^^ These studies indicate that GPIb alpha is not expressed in human cultured endothelial cells and is not involved in adhesion to vWF containing surfaces . ^^^ Thus , in static conditions , cultured endothelial cells adhere to vWF through an alpha vbeta 3 dependent , GPIb alpha independent mechanism . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet membrane glycoprotein ( GP ) Ib 5 9 complex is the receptor for von Willebrand factor and is composed of four membrane spanning polypeptides : GPIb alpha , GPIb beta , GPIX , and GPV . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| GpIb alpha contains binding sites for von Willebrand factor and for thrombin and mediates platelet adhesion to the subendothelium under conditions of high shear stress . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The monoclonal antibody RFF 8 : R / 1 recognises an epitope on von Willebrand factor involved in its interaction with GPIb alpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| This was demonstrated by the increase in MK markers ( GPIIb , GPIIIa , GPIb alpha , GPIX and vWF ) , the appearance of cytoplasmic alpha granules , intracellular membranes resembling demarcation membranes which were immunologically labeled with an GPIIb / IIIa anti antibody , and a small percentage of polyploid cells ( 8N and 16N ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Finally , with an in vitro model system , tumor induced platelet aggregation was enhanced by 127 % ( P < 0 . 001 ) in study patient platelet rich plasma ( PRP ) compared to control PRP and could be completely inhibited ( P < 0 . 0009 ) when both tumor cells and their PRP substrates were incubated with monoclonal antibodies directed against the vWf binding epitope of GPIb alpha and against the GPIb binding epitope of plasma vWf , respectively . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Von Willebrand factor receptor GPIb alpha is expressed by human factor XIIIa positive dermal dendrocytes and is upregulated by mast cell degranulation . ^^^ GPIb alpha , a glycoprotein component of the GPIb 9 5 complex , serves as a platelet membrane receptor that mediates adhesion to von Willebrand factor normally present in the vascular subendothelium . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| DDs express coagulation factor XIIIa and the recently described von Willebrand factor receptor , GPIb alpha , potentially indicating a function in tissue repair and haemostasis , although participation in antigen presentation is also speculated . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The complex , which serves as a platelet receptor for von Willebrand factor , is composed of 4 subunits : GPIb alpha , GPIb beta , GPIX , and GPV . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Furthermore , in a modified Boyden chamber assay , prior exposure to vWf or a GPIb alpha monoclonal antibody , AK 2 , enhanced cell migration . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelet glycoprotein Ib 9 5 ( GPIb 9 5 ) mediates adhesion to von Willebrand factor ( vWF ) in ( patho ) physiological thrombus formation . vWF binds the N terminal 282 residues of GPIb alpha , consisting of an N terminal flank ( His 1 Ile35 ) , 7 leucine rich repeats ( Leu 36 Ala200 ) , a C terminal flank ( Phe 201 Gly268 ) , and a sulfated tyrosine sequence ( Asp 269 Glu282 ) . ^^^ By expressing canine human chimeras of GPIb alpha on Chinese hamster ovary cells , binding sites for functional anti GPIb alpha antibodies to individual domains were previously mapped , and it was shown that leucine rich repeats 2 to 4 were required for optimal vWF recognition under static or flow conditions . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Blockers of VWF binding to GpIb alpha or actin polymerization inhibit the association of alpha actinin with the GpIb 9 complex , but the association of alpha actinin with the GpIb 9 complex is not affected by inhibiting VWF binding to platelet integrin alpha IIb beta 3 ( GpIIb IIIa ) . alpha Actinin becomes tyrosine phosphorylated in response to pathological shear stress , and phosphorylated alpha actinin associates with GpIb 9 . ^^^ These results demonstrate that shear induced VWF binding to GpIb alpha causes enhanced binding of cytoskeletal alpha actinin to GpIb 9 and suggest that alpha actinin , perhaps through tyrosine phosphorylation , serves as an adapter for a signaling complex that could regulate VWF induced platelet aggregation . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| In this study , we have built molecular models of the seven leucine rich repeats of human , canine and mouse GPIb alpha , providing novel insights into the species specific interaction between human vWF and its receptor . ^^^ In addition , five individual mutations within the leucine rich repeats of GPIb alpha associated with the bleeding disorder Bernard Soulier syndrome , that result in dysfunctional vWF binding , were mapped to the model of human GPIb alpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The sulfation of the 3 tyrosine residues 276 , 278 , and 279 in GPIb alpha is an important posttranslational modification that seems to promote the interaction with VWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| In conclusion , hypercholesterolemia primes platelets for recruitment via VWF , GPIb alpha , and P selectin to lesion prone sites , before lesions are detectable . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Glycoprotein ( GP ) Ib / V / IX complex dependent platelet adhesion to von Willebrand factor ( VWF ) is supported by the 45 kd N terminal extracellular domain of the GPIb alpha subunit . ^^^ Recent results with an adhesion blocking antibody ( RAM . 1 ) against GPIb beta , which is disulfide linked to GPIb alpha , have suggested a novel function of this subunit in regulating VWF mediated platelet adhesion , possibly involving its intracellular face . ^^^ A putative cooperation between the GPIb alpha and GPIb beta cytoplasmic domains was investigated by measuring the adhesion under flow to immobilized VWF of K 562 and Chinese hamster ovary ( CHO ) cells transfected with GPIb / ( 5 ) / IX containing mutations in this region . ^^^ A role of the GPIb alpha intracellular domain was also apparent as the VWF dependent adhesion of cells containing deletions of the entire ( Delta 518 610 ) or portions ( Delta 535 568 , Delta 569 610 ) of the GPIb alpha cytoplasmic tail was insensitive to RAM . 1 inhibition . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Fourth , CVX binding to GPIb alpha is disrupted by phenylalanine substitutions at GPIb alpha tyrosine 276 , tyrosine 278 , and tyrosine 279 , which also disrupts von Willebrand factor and alpha thrombin binding to GPIb alpha . ^^^ Furthermore , the binding site on GPIb alpha for CVX may be close to that for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| PIP 3 production and the observed changes in the association between alpha actinin , PIP 2 , and PI 3 KIA are inhibited when VWF binding to GpIb alpha is blocked . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The N terminal domain of GP Ib alpha , which contains the binding sites for VWF and alpha thrombin , crystallized in the tetragonal space group P 4 ( 3 ) with one molecule in the asymmetric unit . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| At a molecular level , this interaction takes place between the A 1 domain of VWF and the GPIb alpha chain of the GPIb 9 complex . ^^^ VWF TASP was found to inhibit specifically botrocetin induced platelet aggregation and to bind both botrocetin and GPIb alpha . ^^^ Modeling studies revealed that the relative orientation of the alpha helices in VWF TASP led to a clash of bound botrocetin and GPIb alpha . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We characterized the mutant GP1BB allele by expression in a cell line ( CHO alpha 9 ) that stably expresses two other components of the vWF receptor , GPIb alpha and GPIX . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The dissociation constants of ristocetin induced ( 125 ) 1 labelled VWF binding to two forms of soluble recombinant GPIb alpha [ ( 1 ) His ( 302 ) Ala , either ( 145 ) Thr ( 145T ) or ( 145 ) Met ( 145M ) ] were not different . ^^^ Four types of Chinese hamster ovary cells expressing full length GPIb alpha beta / IX , 145T with one repeat ( T1R ) , 145M with one repeat ( M1R ) , 145T with four repeats ( T4R ) , and 145M with four repeats ( M4R ) , were prepared , and cell interactions with immobilized VWF were examined under various shear conditions . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Amino acid substitutions in GPIb alpha , may lead to up regulation and spontaneous binding of von Willebrand factor as in Platelet type von Willebrand disease . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Each is an autosomal recessive bleeding disorder in which absence of a protein complex renders the affected platelets incapable of undergoing either vWf mediated adhesion ( BSS ) or fibrinogen mediated aggregation ( GT ) . ( ABSTRACT TRUNCATED AT 400 WORDS ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| A molecular defect involving platelet membrane glycoproteins has been established as the primary abnormality , and the major defect is described as an absence of GPIb , the receptor for von Willebrand factor , which prevents the adhesion of BSS platelets to damaged endothelium . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| At shear stresses of 90 or 180 dyne / cm2 applied for 30 seconds or five minutes , aggregation was either absent or only transient and reversible using severe von Willebrand ' s disease ( vWD ) PRP ( less than 1 % von Willebrand factor , vWF ) ; Bernard Soulier syndrome ( BSS ) PRP ( platelets deficient in the membrane glycoprotein Ib , GPIb ) ; normal PRP plus monoclonal antibody ( MoAb ) to GPIb ; thrombasthenic PRP ( platelets deficient in membrane glycoprotein IIb IIIa complex , GPIIb IIIa ) ; and normal PRP plus MoAb to GPIIb IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelets from a patient with Bernard Soulier Syndrome ( BSS ) which did not bind human 8 : vWF in the presence of ristocetin or aggregate with bovine cryoprecipitate also did not adhere to 8 : vWF coated membranes . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier Syndrome ( BSS ) is a hereditary bleeding disorder which is caused by the absence or the dysfunction of the platelet glycoprotein Ib / IX / V ( GP Ib / IX / V ) complex , the major receptor for von Willebrand factor ( vWf ) . ^^^ BSS is characterized by the presence of giant platelets that show a reduced binding of vWf . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The blood volumes and concentrations of thromboxane B 2 ( TxB 2 ) , platelet factor 4 ( PF 4 ) , and fibrinopeptide A ( FPA ) were measured every 30 seconds in bleeding time blood in normal subjects and in patients with idiopathic thrombocytopenic purpura ( ITP ) , delta and alpha delta storage pool deficiency ( SPD ) , Bernard Soulier Syndrome ( BSS ) , thrombasthenia ( TSA ) , and von Willebrand ' s disease ( vWD ) . ^^^ The bleeding time was greater than 15 minutes in all patient groups and the initial bleeding , as reflected by the initial slope of the fitted blood volume curves , was increased in ITP , BSS , and SPD ( delta SPD in particular ) , but not in vWD and TSA . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) giant platelets have defective and / or deficient glycoprotein ( GP ) Ib / IX complexes , causing absent ristocetin induced aggregation , defective interaction with von Willebrand factor , morphologic abnormality , and a clinical bleeding tendency . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Nilsson et al in vWD in Aland Islands with the recognition of a plasmatic anomaly , later confirmed by Cornu et al to be different from factor 8 deficiency . ( 3 ) The third and crucial development ( glycoprotein era ) ( 1974 1981 ) came from the discovery by Nurden & Caen ( 1974 1975 ) of GPIIb IIIa defect in GT and of GPIb 9 in BSS . ^^^ On everted rabbit subendothelium platelet , adhesion was abnormal in BSS whichever shear stress and at high shear stress in vWD . ( 4 ) The molecular biology era ( 1984 1995 ) with the exquisite recognition of gene or protein anomalies in the above mentioned disorders together with the cloning of the 3 genes [ for vW factor ( vWF ) ( GPIb 9 , GPIIb , and GPIIIa ] . ( 5 ) We are at the dawn of the more crucial era , the antithrombotic therapy acting either on the GPIb vWF complex or on the GPIIb IIIa . ( ABSTRACT TRUNCATED AT 250 WORDS ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is a rare inherited bleeding disorder which is caused by abnormal expression or function of the glycoprotein ( GP ) Ib / IX / V complex , a platelet major receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet membrane glycoprotein ( GP ) Ib 9 5 complex , the major von Willebrand factor receptor on platelets , is absent or dysfunctional in patients with the Bernard Soulier syndrome ( BSS ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is a rare hereditary bleeding disorder and macrothrombocytopenia which is caused by a defect in the platelet glycoprotein Ib / IX / V ( GP Ib / IX / V ) complex , the receptor for von Willebrand factor and thrombin . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is an autosomal recessive bleeding disorder due to quantitative or qualitative abnormalities in the glycoprotein ( GP ) Ib / IX / V complex , the platelet receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Whether GPV deficiency might also cause BSS is unknown as are the roles of GPV in platelet vWF interaction and thrombin signaling . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is an autosomal recessive bleeding disorder due to quantitative or qualitative abnormalities in the glycoprotein ( GP ) Ib / IX / V complex , the platelet receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| GPIbalpha , together with other proteins , constitutes the plasma von Willebrand factor ( vWF ) receptor , which is altered in Bernard Soulier syndrome ( BSS ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We evaluated real time processes of platelet thrombus formation on a collagen surface in a flow chamber with whole blood from patients with various platelet aggregation disorders , such as Bernard Soulier syndrome ( BSS ) , Glanzmann ' s thrombasthenia ( GTA ) , type 3 von Willebrand disease ( vWD ) , and congenital afibrinogenemia ( Af ) , who lack platelet glycoprotein ( GP ) Ib 9 complex , GP IIb IIIa , von Willebrand factor ( vWF ) , and fibrinogen , respectively . ^^^ By contrast , blood from patients with BSS or type 3 vWD showed no platelet surface interaction under high shear ( > / =1 , 210 s ( 1 ) ) but normal thrombus formation under low shear ( < / =340 s ( 1 ) ) . ^^^ When shear rate was increased stepwise to 1 , 500 s ( 1 ) during perfusion , the thrombus growth observed in type 3 vWD or BSS under low shear was arrested , whereas that in control blood was sharply accelerated as a function of shear rate . ^^^ However , Af thrombi formed under such conditions collapsed immediately when shear rate was further increased to 4 , 500 s ( 1 ) , whereas thrombi of type 3 vWD or BSS formed under low shear were stable even when shear rate was elevated to 9 , 000 s ( 1 ) during perfusion . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is an autosomal recessive bleeding disorder caused by quantitative or qualitative abnormalities in the glycoprotein ( GP ) Ib / IX / V complex , the platelet receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier Syndrome ( BSS ) is an autosomal recessive bleeding disorder due to quantitative or qualitative abnormalities in the glycoprotein ( GP ) Ib / IX / V complex , the platelet receptor for von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| There is no consensus , however , on whether the formation of platelet procoagulant activity ( PPA ) is impaired in BSS and , if so , whether this is due to the lack of GPIb 5 9 dependent binding of thrombin or of von Willebrand factor ( VWF ) . ^^^ In BSS PRP addition of ( thrombin free ) fibrin did not increase TG as in normal PRP , supporting our previous hypothesis that the interaction of fibrin , VWF and GPIb triggers PPA development . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bernard Soulier syndrome ( BSS ) is a rare inherited bleeding disorder due to quantitative or qualitative abnormalities in the platelet glycoprotein ( GP ) Ib / IX / V complex , the major von Willebrand factor receptor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The up regulation of von Willebrand factor receptor ( GPIb ) and thrombospondin receptor ( GPIV ) and the down regulation of fibrinogen receptor ( GPIIb / IIIa ) and C3bi receptor ( CD11b ) were found by incubation with MAbs AN 51 ( CD42b ) , OKM 5 ( CD 36 ) , J 15 ( CD41a ) , and OKM 1 ( CD11b ) , respectively . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Other mAb , such as those against the von Willebrand factor receptor ( GPIb ) ( CD42b ) , the thrombospondin receptor ( GPIV ) ( CD 36 ) , and GPIIIa ( CD 61 ) , also showed statistically significant reduction of mAb binding but to a lesser degree . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelets from patients receiving DDAVP for vWD or for platelet dysfunction , had increases in CD42b MoAb and anti GPIb / IX binding ( P < 0 . 01 ) that coincided with shortening of their bleeding time . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Platelet glycoproteins Ib beta ( CD42c ) , 9 ( CD42a ) , and 5 ( CD42d ) , together with GP Ib alpha ( CD42b ) , form a receptor whose interaction with the von Willebrand factor is essential in the initial stages of haemostasis . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Modifications in platelet activation markers ( P selectin [ CD62P ] ) and lysosomal related protein ( UMPS [ CD 63 ] ) , presence of membrane glycoproteins ( GPIb [ CD42b ] , GPIIb IIIa [ CD41a ] , GDIV [ CD 36 ] , binding of von Willebrand factor ( vWF ) , fibrinogen ( Fg ) and factor 5 [ FV ] ) were analyzed in normal donors ( n = 10 ) and in a severe von Willebrand patient ( type 3 ) von Willebrand disease [ vWD ] ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The majority of CD 61 ( + ) cells generated in TPO or PMP based medium were low ploidy 4N and 8N cells , and ex vivo generated CD 61 ( + ) , CD 41 ( + ) , and CD42b ( + ) cells were mainly double positive for FACS measured intracellular von Willebrand Factor ( vWF ) ( 76 . 7 + / 3 . 3 % , 58 . 8 + / 4 . 4 % , and 82 . 7 + / 2 . 5 % , respectively ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We measured the percentages of microplatelets , platelet aggregates and platelets bearing the activation marker C D62P , and bearing molecules forming receptors for fibrinogen ( CD 61 ) and for von Willebrand factor ( CD42b ) using flow cytometry and specific monoclonal antibodies . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Using flow cytometry we measured the percentage of platelet microparticles , platelet platelet aggregates , and surface expression of CD62P ( P selectin ) and CD42b ( a component of von Willebrand factor receptor ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Samples were stained with fluorescent antibodies against markers of platelet activation ( P selectin [ CD 62 ] , lysosomal protein [ CD 63 ] , and fibrinogen and von Willebrand factor receptors [ CD 41 and CD42b , respectively ] ) and analyzed by flow cytometry . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet fibrinogen ( Fg ) receptor ( GPIIb / IIIa ) is an integrin which plays a critical role in hemostasis by recognizing at least the four adhesive ligands : Fg , fibronectin ( Fn ) , vitronectin ( Vn ) , and von Willebrand factor ( vWf ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The GPIIb / IIIa complex functions as a platelet receptor for fibrinogen , von Willebrand factor , fibronectin and vitronectin ; therefore it plays an important role in platelet adhesion and aggregation . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| GPIIb / IIIa ( alpha IIb / beta 3 ) is a member of the integrin family and functions as a receptor for fibrinogen , fibronectin , von Willebrand factor , and vitronectin at the surface of activated platelets . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shear stress induced aggregation requires von Willebrand factor ( vWF ) multimers , extracellular calcium ( Ca2+ ) , adenosine diphosphate ( ADP ) , and platelet membrane glycoprotein ( GP ) Ib and GPIIb IIIa . ^^^ The tetrapeptide RGDS and the monoclonal antibody 10E5 , which inhibit vWF binding to GPIIb IIIa , partially inhibited shear stress induced [ Ca2+ ] 1 and aggregation responses . ^^^ These results indicate that GPIb and extracellular Ca2+ are absolutely required for vWF mediated [ Ca2+ ] 1 and aggregation responses to imposed shear stress , and that the interaction of vWF multimers with GPIIb IIIa potentiates these responses . ^^^ These results suggest that shear stress induces the binding of vWF multimers to platelet GPIb and this vWF GPIb interaction causes an increase of [ Ca2+ ] 1 and platelet aggregation , both of which are potentiated by vWF binding to the platelet GPIIb IIIa complex . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet integrin , glycoprotein IIb IIIa ( GPIIb IIIa ) , is a calcium dependent heterodimer that binds fibrinogen , von Willebrand factor , and fibronectin after platelet activation . ^^^ Electron microscopy of GPIIb IIIa bound to fibronectin revealed GPIIb / IIIa binding sites approximately two thirds of the distance from the amino terminus of each end of the fibronectin molecule , while GPIIb IIIa was found to bind to von Willebrand factor protomers along a rod like region near the central nodule of the molecule . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Willebrand factor and platelet interactions with the vessel wall . von Willebrand factor ( vWF ) is a multimeric glycoprotein which has a dual role in haemostasis , functioning as carrier protein for Factor 8 and mediating platelet adhesion to exposed subendothelium ( SE ) . vWF interacts with components of the SE such as collagen and heparin like glycosaminoglycans as well as with two platelet membrane receptors : glycoprotein ( GP ) Ib and GPIIb / IIIa . ^^^ The role of the vWF GPIb interaction in platelet adhesion is well known ; that of the vWF GPIIb / IIIa interaction has been more recently demonstrated through the use of monoclonal antibodies ( MAbs ) or synthetic peptides blocking vWF binding to GPIIb / IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| A monoclonal antibody against GPIIb , decreased the % CS ( p less than 0 . 01 ) without influencing % C ; VWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| In contrast , a MoAb that binds to a C terminal region of vWF involved in GPIIb : IIIa recognition caused a specific , concentration dependent increase in the quantity of platelet bound fibrin . ^^^ These results support the hypothesis that vWF and fibrin , both of which are multimeric adhesive ligands , compete for occupancy of the GPIIb : IIIa complex on thrombin stimulated platelets . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| These results are consistent with a two site model for platelet adhesion to fibrin , in which the GPIIb : IIIa complex is the primary receptor , with GPIb : vWF providing a secondary adhesion pathway that is especially important at high wall shear rates . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The results of the present study demonstrate that independent modulation of vWF and fibrinogen binding to stimulated platelets can be attained with monoclonal antibodies directed against distinct epitopes of GPIIb / IIIa . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet membrane glycoprotein IIb 10 IIIa heterodimer complex ( GPIIb 10 IIIa ) is the platelet receptor for adhesive proteins , containing binding sites for fibrinogen , von Willebrand factor , and fibronectin on activated platelets . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The functional properties of GPIb and GPIIb / IIIa were evaluated using purified 125I labelled asialo von Willebrand factor ( vWF ) and purified 125I labelled fibrinogen , respectively , in a binding assay . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| We confirmed that a calcium dependent cysteine protease ( CDP ) was present in the sera of each of the 15 patients when we used an assay based on the ability of CDP to proteolyse platelet membrane glycoprotein 1b ( GP1b ) and hence to abolish the ability of CDP treated normal platelets to agglutinate in the presence of ristocetin and von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| In contrast , a monoclonal antibody that blocks the receptor for adhesive proteins on the platelet GPIIb / IIIa complex failed to inhibit the initial response of platelets to high concentrations of IIB vWF . ^^^ Moreover , IIB vWF caused agglutination of formalin fixed platelets that was blocked only by the anti GPIb antibody , suggesting that the binding of vWF to GPIb , even in the absence of ristocetin , results in platelet platelet interaction that is followed by exposure of the GPIIb / IIIa receptors for adhesive proteins . ^^^ In the absence of fibrinogen , however , aggregation was mediated by vWF binding to GPIIb / IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| This system was able to detect an impairment of platelet adhesion dependent on glycoprotein ( GP ) Ib defect ( Bernard Soulier syndrome ) or on low platelet von Willebrand factor content , but was insensitive to platelet GPIIb IIIa defect ( Glanzmann ' s thrombasthenia ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet GPIIb IIIa complex functions as a receptor for fibrinogen , fibronectin , and von Willebrand factor on activated platelets . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| RIPA ( at low ristocetin concentrations ) in the patients ' platelet rich plasma was abolished by a monoclonal antibody ( AP 1 ) to GPIb and was markedly reduced by monoclonal antibodies ( 10E5 and LJP 9 ) that block adenosine diphosphate and thrombin induced binding of vWF and fibrinogen to GPIIb IIIa but was unaffected by an antibody ( LJP 5 ) that only blocks vWF binding . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The platelet membrane glycoproteins IIb ( GpIIb ) and GpIIIa form calcium dependent heterodimers containing binding sites for fibrinogen , von Willebrand factor , and fibronectin . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Exposure of fibrin surfaces to normal plasma before perfusion with severe von Willebrand ' s disease blood did not compensate for the presence of plasma vWF necessary for adhesion . vWF mutants in which the GPIIb : IIIa binding site was mutated or the GPIb binding site was deleted showed that vWF only interacts with GPIb on platelets in supporting adhesion to fibrin and not with GPIIb : IIIa . ^^^ Furthermore , only GPIb , but not GPIIb : IIIa is directly involved in this interaction of vWF with platelets . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Our results suggest that platelet clumping induced by vWF binding to GPIb is responsible for GPIIb IIIa dependent Ca2+ influx . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Complete inhibition of endothelial cell adhesion to vWF was obtained in the presence of F ( ab ' ) 2 of monoclonal antibody 9 to vWF , which blocks vWF binding to platelet GPIIb / IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The binding of Fg to immobilized GPIIb / IIIa , the rate of clot retraction and the adhesion of stimulated platelets to Fg , fibronectin ( Fn ) , vitronectin ( Vn ) , and von Willebrand factor ( vWf ) were inhibited by these antibodies , but not by a control IgG . ^^^ Subsequent studies demonstrated that a peptide corresponding to residues 300 312 of GPIIb alpha can bind to Fg and Vn , and is a potent inhibitor of platelet aggregation and the adhesion of activated platelets to at least four adhesive ligands : Fg , Fn , Vn , and vWf ( 2 ) . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The GPIIb / IIIa vWF interaction is required for adhesion to coated vWF under flow conditions . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| BACKGROUND : Arterial injury is immediately followed by platelet adhesion at the site of injury , a process that requires the interaction of subendothelial von Willebrand factor with the platelet GP1b receptor . ^^^ VCL , a recombinant von Willebrand factor GP1b binding domain , inhibits platelet binding to von Willebrand factor . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| This shear induced platelet aggregation ( SIPA ) is mediated by von Willebrand factor binding to platelet membrane glycoprotein ( GP ) Ib and GPIIb / IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The amino acid sequence of apolipoprotein ( a ) [ apo ( a ) ] reveals an arginyl glycyl aspartate ( RGD ) tripeptide that is the consensus sequence for binding of adhesive plasma proteins of the fibrinolytic system , such as fibrinogen and von Willebrand factor , to the platelet membrane glycoprotein IIb IIIa ( GPIIb IIIa ) complex . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Each vWf subunit has binding sites for collagen , heparin , GP Ib , GPIIb / IIIa and factor 8 . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shear induced p 47 phosphorylation depends entirely on vWF binding to platelet glycoprotein ( Gp ) Ib and GpIIb IIIa , and the specific inhibition of protein kinase C with the staurosporine analogue Ro 31 7549 inhibits the full aggregation response to shear . ^^^ These results indicate that mechanical shear stress induces vWF to bind to platelet GpIb and GpIIb IIIa , stimulating a diacylglycerol independent pathway of protein kinase C activation that contributes to platelet aggregation in response to shear . . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The precise sequence of interactions among von Willebrand factor ( vWF ) , glycoprotein ( GP ) Ib , and GPIIb IIIa during platelet adhesion and subsequent aggregation were resolved by direct real time observation using a computerized epifluorescence video microscopy system . ^^^ Aggregation occurred subsequently and required the binding of ligands , including vWF via its RGD binding domain , to GPIIb IIIa . ^^^ Mechanism ( 2 ) was modeled by producing shear stresses of 90 to 180 dynes / cm2 in a rotational cone and plate viscometer , which aggregates platelets from platelet rich plasma ( PRP ) anti coagulated with citrate , hirudin , or either type of heparin in reactions that require large vWF multimers , Ca2+ , adenosine diphosphate , and both GPIb and GPIIb IIIa . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Radiolabeled vWF attached to both glycoprotein ( GP ) Ib and GPIIb IIIa receptors in the shear field , with complete inhibition of binding occurring with simultaneous blockade of both receptors . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Bitiscetin induced platelet agglutination was dependent on vWF and platelet membrane glycoprotein ( GP ) Ib , but not on Ca2+ and GPIIb / IIIa . vWF bound to bitiscetin but not to botrocetin electroblotted to a PVDF membrane after SDS PAGE and this binding was diminished after reduction of disulfide bonds of bitiscetin . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| RG 12986 , a novel antagonist of platelet aggregation , is a recombinant peptide based on the sequence in von Willebrand factor , which contains the GP1b binding site . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Adhesion to glass coated vWF was partially inhibited by heparin and completely inhibited by prostaglandin 1 ( 2 ) and anti glycoprotein ( GP ) Ib and anti GPIIb IIIa antibodies . vWF dependent adhesion to collagen was not inhibited by heparin , was partially inhibited by anti GPIIb IIIa , and was completely inhibited by prostaglandin 1 ( 2 ) and anti GPIb . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Shear stress induced platelet aggregation requires von Willebrand factor ( vWF ) , platelet glycoprotein ( GP ) Ib , GPIIb IIIa , Ca2+ , and adenosine diphosphate ( ADP ) . ^^^ Recent reports using vWF labeled with either 125I or fluorescein isothiocyanate ( FITC ) have demonstrated that in shear fields , vWF binds to both GPIb and GPIIb IIIa . ^^^ In contrast , blockade of GPIIb IIIa with monoclonal anti GPIIb IIIa antibodies , 10E5 , or c7E3 , or with the GPIIb IIIa blocking tetrapeptide , RGDS had little or no inhibitory effect on platelet vWF binding . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Uninduced MELC expressed detectable levels of mRNAs for acethylcholinesterase ( AChE ) , platelet factor 4 ( PF 4 ) , glycoprotein IIb ( GPIIb ) and von Willebrand factor ( VWF ) , whereas the erythroid alpha and beta globin genes were not transcribed appreciably . ^^^ However , MELC exposed to 5 mM hexamethylene bisacetamide ( HMBA ) or 1 . 5 % dimethyl sulphoxide ( DMSO ) seemed to be channelled towards a mixed erythroid / megakaryocytic phenotype characterized by unaltered levels of VWF mRNA , increased levels of AChE , GPIIb and PF 4 mRNA . and simultaneous induction of the globin genes . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The measurements of vWF capacity to bind to : ( 1 ) platelet glycoprotein ( GP ) Ib in the presence of ristocetin ; ( 2 ) GPIIb / IIIa in the presence of thrombin ; ( 3 ) types 1 and 3 collagen ; ( 4 ) factor 8 ( FVIII ) gave evidence that the functional activity of purified vWF was similar to that of native plasma vWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Inhibition of p 38 MAPK had no effect on VWF induced platelet alpha or lysozomal granule release , expression of activated GPIIb IIIa , modulation of membrane glycoprotein CD 41 , expression of phosphatidylserine as assessed by annexin 5 binding , microparticle formation , or platelet agglutination . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| Increased thrombus formation with patient plasma is completely normalized by blocking the interaction of vWF with the platelet receptors , glycoprotein ( GP ) Ib and GPIIb IIIa , suggesting that the phenomenon is completely mediated by vWF . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| All alleles of GPIIb , GPIIIa , VWF , beta actin , hsp 70 , c mpl , Fli 1 , and FOG 1 genes are transcriptionally active in megakaryocytes from 4N to 32N . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| This suggests racial differences in the interaction of VWF with GP1b but not with subendothelium . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| ADHESION : The platelets adhere to the injured blood vessel wall via their receptors glycoprotein ( GP ) Ib and integrin alpha2bbeta3 ( GPIIb / IIIa ) mediated by the ligands von Willebrand factor ( VWF ) , fibrinogen and others . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| No association was observed with 6 other candidate genes , GP1BA , ITGB 3 , VWF , FGB , IL 6 , or TXA2R . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| The major haplotypes of seven other candidate genes , GP1BA , ITGA2B , ITGB 3 , GP 6 , VWF , FGB , and IL 6 , were not associated with bleeding severity . ^^^ |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|
| Interacting proteins: P07359 and P04275 |
Pubmed |
SVM Score :0.0 |
| NA |
|